Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome

Background. Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibod...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:medRxiv
Auteurs principaux: Borghi, Maria Orietta, Beltagy, Asmaa, Garrafa, Emirena, Curreli, Daniele, Cecchini, Germana, Bodio, Caterina, Grossi, Claudia, Blengino, Simonetta, Tincani, Angela, Franceschini, Franco, Andreoli, Laura, Lazzaroni, Maria Grazia, Piantoni, Silvia, Masneri, Stefania, Crisafulli, Francesca, Brugnoni, Dulio, Muiesan, Maria Lorenza, Salvetti, Massimo, Parati, Gianfranco, Torresani, Erminio, Mahler, Michael, Heilbron, Francesca, Pregnolato, Francesca, Pengo, Martino, Tedesco, Francesco, Pozzi, Nicola, Meroni, Pier Luigi
Format: Artigo
Langue:Inglês
Publié: Cold Spring Harbor Laboratory 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310661/
https://ncbi.nlm.nih.gov/pubmed/32588001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.17.20134114
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires